trending Market Intelligence /marketintelligence/en/news-insights/trending/GT7Xy3VEXL6xG4DWYOcGIA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA approves 1st generic versions of Bristol-Myers, Pfizer's Eliquis

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA approves 1st generic versions of Bristol-Myers, Pfizer's Eliquis

The U.S. Food and Drug Administration approved the first generic versions of Bristol-Myers Squibb Co. and Pfizer Inc.'s blood thinner Eliquis.

The regulator gave the nod to two copies of Eliquis, or apixaban, made by Micro Labs Ltd and Mylan NV, to reduce the risk of stroke and recurrent blockages in the blood vessels due to clots in patients with nonvalvular atrial fibrillation.

Nonvalvular atrial fibrillation is an irregular heart rhythm due to high blood pressure or an overactive thyroid gland, and the cause is not always known. Atrial fibrillation allows blood to pool in the heart and increases the risk of complications like blood clots and strokes.

The Centers for Disease Control and Prevention estimates that between 2.7 million and 6.1 million people in the U.S. have atrial fibrillation, the FDA noted in its Dec. 23 news release.

Bristol-Myers and its partner Pfizer said worldwide sales of Eliquis in the third quarter of 2019 grew 22% year over year to $1.93 billion. Bristol-Myers executives on an Oct. 31 earnings call attributed the growth to demand and volume of prescriptions.